OpenAI Reportedly Eyes Late-2026 IPO Amid Rising Competition and Massive Funding Needs 
SpaceX Updates Starlink Privacy Policy to Allow AI Training as xAI Merger Talks and IPO Loom 
SpaceX Seeks FCC Approval for Massive Solar-Powered Satellite Network to Support AI Data Centers 
Chinalco and Rio Tinto Acquire Controlling Stake in Brazil’s CBA for $903 Million 
Panama Supreme Court Voids Hong Kong Firm’s Panama Canal Port Contracts Over Constitutional Violations 
Bob Iger Plans Early Exit as Disney Board Prepares CEO Succession Vote 
Nvidia Confirms Major OpenAI Investment Amid AI Funding Race 
Meta Stock Surges After Q4 2025 Earnings Beat and Strong Q1 2026 Revenue Outlook Despite Higher Capex 
Panama Supreme Court Voids CK Hutchison Port Concessions, Raising Geopolitical and Trade Concerns 
Federal Judge Signals Possible Dismissal of xAI Lawsuit Against OpenAI 
Pentagon and Anthropic Clash Over AI Safeguards in National Security Use 
American Airlines Plans Return to Venezuela Flights After U.S. Lifts Ban 
Apple Earnings Beat Expectations as iPhone Sales Surge to Four-Year High 
Using the Economic Calendar to Reduce Surprise Driven Losses in Forex 
Boeing Secures New Labor Contract With Former Spirit AeroSystems Employees 
Dublin, May 30, 2017 -- Research and Markets has announced the addition of the "Osteoporosis Market and Forecast Analysis" report to their offering.
Osteoporosis is the most common metabolic bone disorder, and is characterized by low bone mass accompanied by microarchitectural deterioration of bone tissue. The consequent increase in bone fragility results in osteoporosis patients being prone to sustaining fractures. Although the majority of osteoporosis patients are postmenopausal women, it is not a female-only disease.
It is estimated that one in three women and one in five men aged over 50 years will sustain an osteoporosis-related fracture, and the associated complications represent a huge socioeconomic burden. Treatment of osteoporosis can be a challenge as bone loss is essentially symptomless until a fracture occurs, which can lead to difficulties with diagnosis and patient compliance.
Key Topics Covered:
1. EPIDEMIOLOGY: OSTEOPOROSIS
- Executive Summary
- Disease Background
- Sources and Methodology
- Forecast: Osteopenia
- Forecast: Osteoporosis
- Epidemiologist Insight
- Strengths and Limitations
- Appendix: Additional Sources
2. MARKETED DRUGS: OSTEOPOROSIS
- Product Overview
- Bisphosphonates
- Estrogens and SERMs
- Calcitonin
- Other Drug Classes
- Product profile: Forteo
- Product profile: Prolia
3. PIPELINE: OSTEOPOROSIS
- Clinical Pipeline Overview
- Comparator Therapy
- Recently Discontinued Drugs
- Product profile (late stage): Evenity
- Product profile (late stage): abaloparatide
For more information about this report visit http://www.researchandmarkets.com/research/8qtmv3/osteoporosis
CONTACT: Research and Markets
Laura Wood, Senior Manager
[email protected]
For E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900
U.S. Fax: 646-607-1907
Fax (outside U.S.): +353-1-481-1716
Related Topics: Endocrine and Metabolic Disorders Drugs, Musculoskeletal Disorders Drugs
